Acute myeloid leukemia (AML) treatment cost in Busan

Your first spend is the work-up, not the treatment — the typical items, priced from this registry where we hold them.

Consultation fees from our specialist registry; procedure prices from this condition's mapped diagnostics. Unverified prices are labeled on their own pages.

The same care market across the registry — cheapest entry first. Cheapest ≠ best: the MCI column grades each market as its data lands.

• Public-system wait at home (UK)NHS England referral-to-treatment statistics, Apr 2026 · Canada (CIHI) next 11.9-week median
• Recruiting acute myeloid leukemia (aml) trials in South KoreaClinicalTrials.gov — recruiting "cancer" studies with a South Korea site · queried 2026-07-09 811 studies
• JCI-accredited organizations in South KoreaJCI public directory, country-wide (all specialties) Not yet sourced

Cheapest entry price per city with the size of its priced treatment menu and specialist density — countable signals only, "—" is never guessed.

The best hospitals first — Newsweek World's Best national top 10 lead, then our connected-chain grade. Re-rank by rating or reviews.

Destination-safety factor for South Korea: ×1.00 — Level 1 — Exercise Normal Precautions (the lowest advisory tier) (US State Dept Travel Advisory, 2025-08). Applies equally to every hospital here; it separates this market from higher-risk destinations.

Epidemiology slots — filled only from named registry sources, never estimated.

Having your existing diagnosis re-read here is the cheapest way to test a hospital's quality before booking anything. Prices land per hospital with sources — never estimated.

• Remote records review — written second opinion your existing scans, pathology and reports, reviewed without flying Not yet priced
• Video consultation with a specialist live case discussion after the review Not yet priced
• In-person specialist consultation reference price if you're already here Not yet priced

A second opinion changes the plan often enough that specialists expect to be asked for one — it's a normal request, not an insult. Remote-review prices are being collected per hospital.

How the treatment decision is typically made for this condition — your specialist confirms the path for your case.

1. 1

   See the right specialist

   Care for acute myeloid leukemia starts with a specialist, who confirms the diagnosis and plans the next steps.

2. 2

   Diagnosis & tests

   The diagnosis is confirmed with Blood Tests or Tissue and Specimen Analysis (Biopsy), which also show how far it has progressed (staging).

3. 3

   Treatment options

   Options include Bone Marrow Transplant (for leukemia, lymphoma, myeloma, aplastic anemia, sickle cell disease), Chemotherapy, Targeted Therapy or Radiation Therapy — weighed on outcome, downtime, risk and total cost. See the priced menu and decision factors below.

4. 4

   Treatment

   The chosen treatment plan is carried out — every option below links to its own price page with a recovery timeline.

5. 5

   Follow-up & monitoring

   Scheduled scans and check-ups confirm the result and catch any recurrence early; remote follow-up is common for international patients.

Framework pathway modeled by field — per-condition clinical pathways replace it as they're sourced.

Specialist types by pathway phase — never named individuals — with real consultation fees where we hold them. Each links to its own price page.

• Diagnosis Radiologist reads your imaging Fee not yet priced
• Diagnosis Pathologist confirms the diagnosis from the biopsy Fee not yet priced
• Decision & systemic treatment Oncologist stages the disease and owns the treatment plan Fee not yet priced
• Local treatment Radiation therapist plans and delivers radiotherapy Fee not yet priced

Fees are city-level consultation ranges from our specialist registry (imported, re-verified over time). Doctors are hospital attributes — you choose the provider on its hospital page, never a named individual here.

What actually decides between the treatments above — and the checklist an expert would put to the specialist.

A planning frame — suitability is always the specialist's call.

What matters if it goes wrong, and what it takes to get there — country-level, verifiable guidance in one place.

Visa

Most Western nationalities (US, UK, EU/Schengen, Australia, Canada, New Zealand, Japan) enter visa-free for short medical or tourist visits. The K-ETA (electronic travel authorization) requirement is temporarily WAIVED for 67 countries and territories through 31 December 2026 — eligible travellers enter without applying for a K-ETA; the requirement is expected to resume 1 January 2027. Confirm your nationality's current rule before travelling.

Medical / long-stay visa

For treatment, foreign patients typically use the C-3-3 medical tourism visa (short-term, stays up to 90 days, generally not extendable beyond 90 days except in special circumstances). For treatment or recovery longer than 90 days, patients change to or apply for the G-1-10 long-term medical treatment visa, which can be extended inside Korea; it requires hospital documentation (medical opinion, treatment schedule, payment records). Applications must be tied to a medical institution registered with KTO/KHIDI.

Arrival

From 1 January 2026, all foreign arrivals must file the mandatory digital e-Arrival Card online (within 3 days before arrival) — it replaces the paper disembarkation card and is a declaration, not a visa. Travellers who hold an approved K-ETA are exempt from the arrival card, but nationals of K-ETA-waived countries (US, UK, EU, Japan, etc.) must still complete the e-Arrival Card.

Currency

South Korean Won (KRW, ₩)

Languages

Korean; English widely spoken in international-patient centers at major hospitals, with interpreter services in multiple languages

Traveller safety

Very safe for visitors

Legal recourse

Established malpractice recourse

Insurance

Medical-travel & complication cover widely available

International patients

Hospitals accustomed to international patients

General guidance from public sources — confirm current rules for your nationality. Verified against: Korea Immigration — K-ETA temporary exemption extended to 31 Dec 2026 (MOFA/KPMG GMS alert) · Korea e-Arrival Card mandatory from 1 Jan 2026 · Medical Korea — medical visa (C-3-3 / G-1-10), KHIDI · MOHW — Korea attracts 1.17 million foreign patients in 2024.

Who treats acute myeloid leukemia (aml), and nearby diagnoses in the same field.

Dots carry the lens colors — teal opens a specialist page, red another condition, both priced for Busan.

How much of this page is verified data — every section carries a chip telling you where its numbers come from.